Company: PTPI
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001410578-25-001811
Chunk: 2

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1F
Chunk 2
---
ITEM 1. UNAUDITED FINANCIAL STATEMENTS.

PETROS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

​

​​​​​​​​​June 30, ​December 31, ​    2025    2024Assets ​   ​  Current assets: ​   ​  Cash and cash equivalents​$ 7,321,501​$ 1,718,645Prepaid expenses and other current assets​  75,342​  885Current assets of discontinued operations​​ —​​ 5,574,748Total current assets​  7,396,843​  7,294,278​​​​​​ ​Non-current assets held for sale​​ —​​ 3,341,032Total assets​$ 7,396,843​$ 10,635,310​​​​​​​Liabilities, Convertible Redeemable Preferred Stock and Stockholders’ Equity (Deficit) ​ ​​   Current liabilities:​ ​​   Accounts payable​​ 970,025​​ 764,333Accrued expenses​  260,624​  99,641Accrued Series A Convertible Preferred payments payable​  1,715,711​  1,909,496Warrant Liability​  3,600​  —Current liabilities held for sale​​ —​​ 15,254,195Total current liabilities​  2,949,960​  18,027,665​​​​​​​Non-current liabilities held for sale​  —​ ​ 75,223Total liabilities​$ 2,949,960​$ 18,102,888​​​​​​​Commitments and contingencies (see note 9)​​​​​​Series A convertible redeemable preferred stock (par value $0.0001 per share and $1,000 stated value), 15,000 and 15,000 shares authorized at June 30, 2025, and December 31, 2024, respectively; 0 and 0 shares issued and outstanding at June 30, 2025, and December 31, 2024, respectively​​ —​​ —​​​​​​​Stockholders’ Equity (Deficit):​  ​​   Series B convertible redeemable preferred stock (par value $0.0001 per share and $1,000 stated value),